Centauri Therapeutics, a British immunotherapy company, has received an $8.1 million investment from the AMR Action Fund to support development of its broad-spectrum antibiotic candidate. CIDRAP has the news.
The money will “help support the completion of phase 1 clinical studies for CTX-187, a novel antibiotic that employs a dual-mechanism action to target clinically prevalent and multidrug-resistant gram-negative bacteria. The drug is built on Centauri's Alphamer platform, which harnesses the immune system to target pathogenic bacteria.”
AMR Action Fund is a venture capital fund “focused on development of novel antimicrobial therapeutics for priority pathogens.” Centauri’s CEO said the investment enabled a “clear path to progress CTX-187 beyond Phase I trials and onto the development of a Phase II-ready asset.” The fund was launched in 2020 with the aim of investing $1 billion in “small and mid-sized biotech companies with promising antimicrobial products.”
